You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Patent: 6,667,041


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,667,041
Title: Use of neurotoxin therapy for treatment of urologic and related disorders
Abstract:The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
Inventor(s): Schmidt; Richard A. (Arvada, CO)
Assignee: The Regents of the University of Colorado (Boulder, CO)
Application Number:09/978,982
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 6,667,041

Introduction

United States Patent 6,667,041, though not specifically detailed in the provided sources, can be analyzed through a general framework that applies to patent claims and the broader patent landscape. This analysis will cover key aspects such as patent validity, the importance of prior art, the role of administrative challenges, and the economic value of patents.

Understanding the Patent

To begin with, it is crucial to understand the specifics of the patent in question. This includes the invention's description, claims, and the technological field it pertains to. For example, if the patent is related to nanotechnology, it would fall under specific classifications such as the USPTO's cross-reference-art collection class 977, or the EPO's Y01N class[1].

Patent Validity and Prior Art

Patent validity is a critical aspect of any patent analysis. This involves a thorough search of prior art to ensure that the invention is novel and non-obvious. A patentability search, as offered by services like Clarivate, identifies references that disclose the same or similar inventions, helping to determine if the claims should be revised[3].

Backward and Forward Citations

Analyzing backward citations (citations to prior art) and forward citations (citations from other patent applications) provides insights into the patent's influence and value. Backward citations indicate the influence of past inventive activities, while forward citations are indicators of the economic or technological value of the patent[1].

Administrative Challenges

The Leahy-Smith America Invents Act (AIA) introduced significant changes to U.S. patent law, including the creation of the Patent Trial and Appeal Board (PTAB). PTAB allows for administrative challenges such as Inter Partes Review (IPR) and Post-Grant Review (PGR), which can be used to challenge the validity of patents. This process is often faster and less expensive than judicial proceedings, making it a crucial consideration for patent holders and challengers alike[2].

Subject Matter Eligibility

For patents facing section 101 rejections, particularly those in emerging fields like AI, the subject matter eligibility analysis is pivotal. The USPTO's two-pronged framework, as outlined in the 2024 Guidance Update, emphasizes the importance of demonstrating a specific, concrete technological advancement or solution to a technical problem. This is particularly relevant under Prong Two of Step 2A, where claims must show an improvement to the functioning of a computer or another technical field[5].

Economic Value of Patents

The economic value of a patent can be assessed using various methods such as cost, income, and market approaches. For instance, the income approach considers the future benefits provided by the patent, while the market value is determined by what a willing buyer would pay for a similar asset. The median asking price for a patent can range from $108,000 to $250,000 per family, depending on the industry and the specific asset[4].

Impact on Innovation and Litigation

The validity and strength of a patent can significantly impact innovation and litigation. Strong, valid patents can encourage investment in research and development, while weak or overly broad patents can lead to unnecessary litigation and stifle innovation. The PTAB's role in weeding out poor-quality patents is intended to reduce such issues, although critics argue that it may create uncertainty and discourage investments in patent-intensive industries[2].

Case Study: Nanotechnology Patents

In the context of nanotechnology, patents have seen a remarkable increase since the mid-1990s. The EPO's definition of nanotechnology, which includes entities with a controlled geometrical size below 100nm, helps in identifying and analyzing nanotechnology patents. This analysis can reveal trends, technological dependencies, and breakthroughs in the field[1].

Key Takeaways

  • Patent Validity: Ensuring a patent's validity through thorough prior art searches and administrative challenges is crucial.
  • Subject Matter Eligibility: Demonstrating a specific technological advancement is key for overcoming section 101 rejections.
  • Economic Value: Patents can be valued using cost, income, and market approaches, with significant variations depending on the industry.
  • Innovation and Litigation: Strong patents encourage innovation, while weak patents can lead to unnecessary litigation.
  • Administrative Challenges: PTAB and IPR/PGR processes are vital for challenging patent validity efficiently.

FAQs

Q: What is the significance of backward and forward citations in patent analysis? A: Backward citations indicate the influence of past inventive activities, while forward citations are indicators of the economic or technological value of the patent[1].

Q: How does the PTAB impact patent litigation? A: The PTAB provides a faster and less expensive way to challenge patent validity compared to judicial proceedings, which can reduce litigation costs and uncertainty[2].

Q: What are the key valuation methods for patents? A: The key valuation methods include the cost approach, income approach, and market approach, each providing a different perspective on a patent's value[4].

Q: Why is subject matter eligibility important for AI inventions? A: Subject matter eligibility is crucial for AI inventions as it determines whether the claims are directed to a specific, concrete technological advancement or solution to a technical problem, overcoming section 101 rejections[5].

Q: How do patent classifications help in identifying and analyzing patents? A: Patent classifications, such as the USPTO's class 977 or the EPO's Y01N, help in identifying and analyzing patents within specific technological fields, ensuring that the invention is novel and non-obvious[1].

Sources

  1. OECD: Capturing Nanotechnology's Current State of Development via Patent Analysis.
  2. Congressional Research Service: The Patent Trial and Appeal Board and Inter Partes Review.
  3. Clarivate: Patent Search Services - Patent Validity Search.
  4. Perpetual Motion Patents: The Value of a Patent.
  5. Baker Botts: The Importance of Prong Two of Step 2A for AI Inventions.

More… ↓

⤷  Subscribe

Details for Patent 6,667,041

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. BOTOX COSMETIC onabotulinumtoxina For Injection 103000 December 09, 1991 ⤷  Subscribe 2017-07-15
Abbvie Inc. BOTOX onabotulinumtoxina For Injection 103000 December 09, 1991 ⤷  Subscribe 2017-07-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 6,667,041

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 9903483 ⤷  Subscribe
United States of America 9066943 ⤷  Subscribe
United States of America 8840905 ⤷  Subscribe
United States of America 8062643 ⤷  Subscribe
United States of America 8057807 ⤷  Subscribe
United States of America 7968104 ⤷  Subscribe
United States of America 7470431 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.